Openings for Technical Associates (40 Posts) on Contractual Basis at Indian Pharmacopoeia Commission, Ghaziabad, Last Date 2nd March 2016

The Indian Pharmacopoeia Commission (IPC) is an Autonomous Body under Ministry of Health & Family Welfare, Govt. of India primarily with the objectives of regularly updating the Indian Pharmacopoeia by publishing new edition and its addenda, National Formulary of India and other related tasks such as preparing, certification and distribution of reference substances & functions as National Coordination Centre (NCC) for Pharmacovigilance Programme of India (PvPI).

We are looking forward for qualified personnel to fill up 40 posts of Technical Associates (for NCC & ADR Monitoring Centres) in PvPI on Contract basis having Master’s Degree in Pharmaceutical Sciences or M.B.B.S/ B.D.S/ Pharm. D or equivalent. Preference will be given to young, dynamic personnel having experience in Pharmacovigilance and proficiency in Computer Applications. Consolidated emolument @ Rs. 25,000/- per month will be paid by IPC. 

The job description of the post is:- 

* Collection of ADR Reports. 

* Follow up with the reporter/patient for Completeness as per SOPs. 

* Data Entry in VigiFlow. 

* Reporting to NCC-PvPI through VigiFlow with the source data (Original)attached each ADR case. 

* Training/Sensitization/Feedback to physicians through news letter circulated by the NCCPvPI.

* Other activities as assigned by competent authority from time to time. 

Applications are invited from citizens of India on the application format which can be downloaded from the website: www.ipc.gov.in of the Commission together with the attested copies of supporting documents within 15 days from the date of advertisement. 

The competent authority reserves the right to increase or decrease the number of vacancies and rejection and/or all applications received without assigning any reason. Selected candidates shall be posted in any of the AMCs under PvPI across the country/NCC-PvPI, IPC, Ghaziabad.

Download Application

Walk-In-Interview for Liva Pharmaceuticals Limited-A Zydus Group on 14th February 2016 at Hyderabad, India

Bharat Biotech gets breakthrough in developing Zika vaccine

Vaccines manufacturer, Bharat Biotech, announced a breakthrough in developing the world’s first Zika vaccine. The Hyderabad-based company has submitted two vaccine candidates — one inactivated and one recombinant — to the Indian government.

The company maintain that pre-clinical studies will be concluded in the next five months, after which the process for regulatory approval will commence.

An inactivated vaccine is when the disease-causing microbe is killed, typically, using chemicals, heat, or radiation. Such a vaccine is more stable and safer than live vaccines. A recombinant vaccine is a vaccine produced through recombinant DNA technology. This involves inserting the DNA encoding an antigen (such as a bacterial surface protein) that stimulates an immune response.

Dr. Krishna Ella, Chairman and Managing Director of the company said that one the two candidates is in advanced stage of development and can be ready soon. “In the coming two weeks, we will be able to start animal tests in one of the two candidates. Since this is a pandemic situation, we are hoping that the Indian government will move quickly of giving requisite approvals for the trials,” said Dr Ella.  

Bharat Biotech has submitted necessary information to Indian Council of Medical Research (ICMR) four days ago. The company is now looking to seek Prime Minister Narendra Modi’s approval to expedite regulatory clearances. “When Ebola vaccine candidates were being discussed, the company had skipped phase 2 trials and went on to phase three with a small sample size. Given the urgency of the situation, something of that sort will be required,” he added. Currently, getting regulatory approvals takes for conducting clinical trials in India can take up to 6-8 months.

Bharat Biotech filed patents for both vaccine candidates in July 2015, Dr Ella informed. He said that since the company already worked on chikungunya, this was the next logical step. “At the time we started working on the Zika vaccine, there was not a market incentive or any demand for it- largely because the symptoms are mild. But we were already working in chukungunya and our hypothesis was that the same vector transmits this disease as well, so we thought we need to look at this aspect as well,”

Source: The Hindu